The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review

In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year, immunotherapy modulators inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Odiase, Otasowie, Noah-Vermillion, Lindsay, Simone, Brittany A., Aridgides, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189418/
https://www.ncbi.nlm.nih.gov/pubmed/34123823
http://dx.doi.org/10.3389/fonc.2021.663749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189418/
https://www.ncbi.nlm.nih.gov/pubmed/34123823
http://dx.doi.org/10.3389/fonc.2021.663749

Ejemplares similares